Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by IamFlooredon Apr 17, 2020 11:36am
216 Views
Post# 30921998

Why did this deal fall through?

Why did this deal fall through?Just asking someone out there who is knowledgeable with the inside management team at KLY. I read that David Basso appeared to be involved with several biotech start up companies and was a major shareholder in many of them. On March 5, 2020 media release, Kalytera was to aquire Stero Biotech. Additional information talked about closing conditions involving a 100:1 share consolidation and a 10 million dollar private placement. I also read a source that Mr. Basso appeared to be the CEO of Stero Biotech. And on the closing of the deal, he would become the CEO and Chairman of Kalytera. And, he would be replacing the current board of directors. IF this is all true, is there no conflict of interest here or violation of any securites regulations. Just wondering? Intelligent answers only please? 
<< Previous
Bullboard Posts
Next >>